ASH 2021: highlights in CLL clinical trials

Treatments such as ibrutinib and venetoclax, which target the Bruton tyrosine kinase (BTK) pathway and the B-cell lymphoma 2 (BCL-2) protein respectively, have proven to be efficacious as targeted therapies for previously untreated patients with chronic lymphocytic leukemia (CLL). For patients who have progressed on existing therapies, novel BTK inhibitors such as pirtobrutinib and MK1026 represent promising alternative treatment options.

In today’s podcast, Jennifer Woyach, MD and Adam Kittai, MD, Ohio State University College of Medicine in Columbus, OH, provide their perspectives on key themes and topics in the treatment and management of CLL. They evaluate findings from the CAPTIVATE, GLOW and CLL13 clinical trials, long-term follow up data of the ALLIANCE A041202 and SEQUOIA trials, novel agents and the role of MRD in CLL.

This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.